Self Medication Japan, Inc.
Established on December 3, 1999 in Japan.
Our main activities are:
・Export of proprietary functional ingredients and finished products for dietary supplements
・Research, Development and Production of proprietary functional ingredients for dietary supplements
・Direct Marketing of dietary supplements in Japan
・7034002 Angiotensin converting enzyme inhibitor (USA)
・2,318,494 Angiotensin converting enzyme inhibitor (Canada)
・3592593 Angiotensin converting enzyme inhibitor (JAPAN)
・4295886 Method for Peptide Refinement (JAPAN)
・3911366 α-glucosidase inhibitor (JAPAN)
・6299911 Extract of Touchi containing an alpha-glucosidase inhibitor (USA)
・69903911.8 ALPHA-GLUCOSIDASE INHIBITOR (Germany)
・1025851 ALPHA-GLUCOSIDASE INHIBITOR（UK）
・1025851 ALPHA-GLUCOSIDASE INHIBITOR（France）
・99801464.8 Alpha-glucosidase inhibitor (China)
・3676637 Method of manufacturing α-glucosidase inhibitor (JAPAN)
・4429588 Method of manufacturing hypolipidemic agent (JAPAN)
EU NOVEL FOOD
Self affirmed GRAS
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.